Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6(1):35-47.
Wasitthankasem R, Posuwan N, Vichaiwattana P, et al. Correction: Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey. PLoS One 2016;11(2):e0152451.
Suwanagool S, Tieangrim S, Ratanasuwan W, et al. Sero- prevalence of anti-HCV among HIV-infected persons and general population. J Med Assoc Thai 1995;78(11):611-7.
Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am 2015;44(4):717-34.
Grebely J, Raffa JD, Lai C, et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007; 21(7): 447-51.
Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112(2):463-72.
Vigano M, Colombo M. Extrahepatic Manifestations of Hepatitis C Virus. Gastroenterol Clin North Am 2015;44 (4):775-91.
Negro F, Forton D, Craxi A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015;149(6):1345-60.
Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120(12):1034-41.
Ozkok A, Yildiz A. Hepatitis C virus associated glome-rulopathies. World J Gastroenterol 2014;20(24):7544-54.
Kidney Disease: Improving Global Outcome (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;(109): S1-99.
Messina JP, Humphreys I, Flaxman A, et al. Global distri- bution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61(1):77-87.
Apichartpiyakul C, Apichartpiyakul N, Urwijitaroon Y, et al. Seroprevalence and subtype distribution of hepatitis C virus among blood donors and intravenous drug users in northern/northeastern Thailand. Jpn J Infect Dis 1999; 52(3):121-3.
Swain MG, Lai MY, Shiffman ML, et al. A sustained vi- rologic response is durable in patients with chronic hepa- titis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139(5):1593-601.
Darling JM, Lemon SM, Fried MW. Part V: Viral Hepati- tis; Hepatitis C. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff’s Disease of the Liver, 11th edition 2011:582-652.
Tillmann HL, McHutchison JG. Hepatitis C. In: Boyer TD, Manns MP, Sanyal AJ, editors. Zakim&Boyer’s Hep- atology: A Textbook of Liver Disease, 6th edition. 2012; Chapter31:564-98.
Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011;55(1):69-75.
Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016;43(12):1276-92.
Gotte M, Feld JJ. Direct-acting antiviral agents for hepati- tis C: structural and mechanistic insights. Nat Rev Gastro- enterol Hepatol 2016;13(6):338-51.
Manns MP, Cornberg M. Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis 2013;13(5): 378-9.
Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370(21):1993-2001.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treat- ment options. N Engl J Med 2013;368(20):1867-77.
Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infec- tion. N Engl J Med 2014;370(16):1483-93.
Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofos- buvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370(20):1889-98.
Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gas- troenterology 2015;149(3):649-59.
Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12- week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61(4):1127-35.
Thai Association for the Study of the Liver (THASL). Thailand Practice Guideline for Management of Chronic hepatitis C 2016. (Accessed June 20, 2016 at http://www. thasl.org/files/31.Hep%20C%20Guideline%202016.pdf).
Curry MP, Forns X, Chung RT, et al. Sofosbuvir and riba- virin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148(1):100-7.
